BIOMAT Database Logo BIOMAT Database Logo

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. 2012

K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.

The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 10(6) CD34+ cells/kg: 81.6%; >5.0 × 10(6) CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 10(6) CD34+ cells/kg: 64.8%; >5.0 × 10(6) CD34+ cells/kg: 12.6%; P<0.0001) and also significantly higher in HL patients (>2.0 × 10(6) CD34+ cells/kg: 81.5%; >5.0 × 10(6) CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D001781 Blood Component Removal Any procedure in which blood is withdrawn from a donor, a portion is separated and retained, at the same time the remainder is returned to the donor. Apheresis,Pheresis,Aphereses,Blood Component Removals,Phereses,Removal, Blood Component
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005062 European Union An economic union with the principal objectives of free movement of goods, capital, and labor. The constituent countries are Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden. (https://europa.eu/european-union/about-eu/countries accessed 12/31/2020) Common Market,Euratom,European Atomic Energy Community,European Coal and Steel Community,European Common Market,European Community,European Economic Community,Community, European Economic,EEC,Economic Community, European,Common Market, European,Common Markets,Common Markets, European,Communities, European,Communities, European Economic,Community, European,Economic Communities, European,European Common Markets,European Communities,European Economic Communities,Market, Common,Market, European Common,Union, European
D005260 Female Females
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic

Related Publications

K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
January 2010, The Annals of pharmacotherapy,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.
November 2012, Transfusion,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
January 2009, Drugs,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
July 2012, Pharmacotherapy,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
August 2011, Drugs,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
December 2013, Journal of clinical apheresis,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
February 2010, Bone marrow transplantation,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
December 2014, Journal of clinical apheresis,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
June 2013, Bone marrow transplantation,
K Hübel, and M M Fresen, and J F Apperley, and G W Basak, and K W Douglas, and I H Gabriel, and C Geraldes, and O Jaksic, and Z Koristek, and N Kröger, and F Lanza, and R M Lemoli, and G Mikala, and D Selleslag, and N Worel, and M Mohty, and R F Duarte
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
August 2016, Expert review of hematology,
Copied contents to your clipboard!